Cover Image
市場調查報告書

酸性神經磷脂(酉每)缺乏症(尼曼匹克症):開發中產品分析

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 283204
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
酸性神經磷脂(酉每)缺乏症(尼曼匹克症):開發中產品分析 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2015
出版日期: 2015年10月14日 內容資訊: 英文 61 Pages
簡介

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)以溶小體儲積症的1個,是帶來代謝的影響,遺傳基因的突然變異起因於的疾病。 被體內的細胞,尤其是網內系細胞(單核吞噬細胞系)sufingo脂質積蓄。 症狀,肝臟肥大,腦功能障礙,步行困難,吞嚥障礙,接觸過敏,表達困難,筋緊張的消失,學習障礙等能看。

本報告提供全球酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的開發中產品的開發情形相關分析,送交調查了開發中產品的最新趨勢,及臨床實驗的各階段有的產品的一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發的發展情形),最新的產業趨勢等的結果。

簡介

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)概要

治療藥的開發

  • 面向酸性神經磷脂(酉每)缺乏症(尼曼匹克症)開發中產品的概要

在各企業正在開發的酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥

在大學/研究機關研究中的酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥

開發中產品的概要

  • 臨床實驗的初期階段有的產品
  • 在藥物研發·前臨床階段的產品

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥:開發中的產品的一覽(各企業)

按酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥:研究中的產品的一覽(大學/研究機關)

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的開發治療藥的企業

  • Genzyme Corporation
  • La Jolla Pharmaceutical Company
  • Merck & Co., Inc.
  • Okklo Life Sciences BV
  • Orphazyme ApS

酸性神經磷脂(酉每)缺乏症(尼曼匹克症):治療藥的評估

  • 是單劑治療藥的情況
  • 按標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • arimoclomol
  • Delta-tocopherol
  • LJPC-0712
  • ML-SA1
  • OKL-1014
  • olipudase alfa
  • OR-0005
  • Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease
  • vorinostat
  • VTS-270

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥:最新的藥物簡介

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥:開發中止的產品

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)的治療藥:開發暫停的產品

酸性神經磷脂(酉每)缺乏症(尼曼匹克症)相關產品的開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7275IDB

Summary

Global Markets Direct's, 'Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2015', provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Overview 7
  • Therapeutics Development 8
  • Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Overview 8
  • Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis 9
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Development by Companies 10
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Investigation by Universities/Institutes 11
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Products Glance 12
  • Clinical Stage Products 12
  • Early Stage Products 13
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Development by Companies 14
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Investigation by Universities/Institutes 15
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Companies Involved in Therapeutics Development 16
  • Genzyme Corporation 16
  • La Jolla Pharmaceutical Company 17
  • Merck & Co., Inc. 18
  • Okklo Life Sciences BV 19
  • Orphazyme ApS 20
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Target 22
  • Assessment by Mechanism of Action 24
  • Assessment by Route of Administration 26
  • Assessment by Molecule Type 28
  • Drug Profiles 30
  • arimoclomol - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Bryostatin-1 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Delta-tocopherol - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • LJPC-0712 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • ML-SA1 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • OKL-1014 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • olipudase alfa - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • OR-0005 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • vorinostat - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • VTS-270 - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Recent Pipeline Updates 48
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects 53
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Product Development Milestones 54
  • Featured News & Press Releases 54
  • Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease 54
  • Jun 15, 2015: Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients 54
  • Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C 55
  • Jun 04, 2015: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa 56
  • Apr 15, 2015: Orphazyme Forms Scientific Advisory Board and Confirms the Enrolment Initiation for the Clinical Programme 56
  • Feb 12, 2015: Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network's WORLD Symposium 2015 57
  • Jan 26, 2015: FDA grants orphan drug designation for Arimoclomol 57
  • Jan 26, 2015: Orphazyme to present at the Gordon Research Conference on Lysosomal Diseases 15-19 March in Galveston, TX 58
  • Oct 20, 2014: COMP issues positive opinion on orphan drug application for Arimoclomol 58
  • Oct 06, 2014: Orphazyme in final preparation stages for a Phase II/III clinical trial 58
  • Appendix 60
  • Methodology 60
  • Coverage 60
  • Secondary Research 60
  • Primary Research 60
  • Expert Panel Validation 60
  • Contact Us 60
  • Disclaimer 61

List of Tables

  • Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2015 8
  • Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2015 9
  • Number of Products under Development by Companies, H2 2015 10
  • Number of Products under Investigation by Universities/Institutes, H2 2015 11
  • Comparative Analysis by Clinical Stage Development, H2 2015 12
  • Comparative Analysis by Early Stage Development, H2 2015 13
  • Products under Development by Companies, H2 2015 14
  • Products under Investigation by Universities/Institutes, H2 2015 15
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Genzyme Corporation, H2 2015 16
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by La Jolla Pharmaceutical Company, H2 2015 17
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Merck & Co., Inc., H2 2015 18
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Okklo Life Sciences BV, H2 2015 19
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Orphazyme ApS, H2 2015 20
  • Assessment by Monotherapy Products, H2 2015 21
  • Number of Products by Stage and Target, H2 2015 23
  • Number of Products by Stage and Mechanism of Action, H2 2015 25
  • Number of Products by Stage and Route of Administration, H2 2015 27
  • Number of Products by Stage and Molecule Type, H2 2015 29
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Recent Pipeline Updates, H2 2015 48
  • Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects, H2 2015 53

List of Figures

  • Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2015 8
  • Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2015 9
  • Number of Products under Development by Companies, H2 2015 10
  • Number of Products under Investigation by Universities/Institutes, H2 2015 11
  • Comparative Analysis by Clinical Stage Development, H2 2015 12
  • Comparative Analysis by Early Stage Products, H2 2015 13
  • Assessment by Monotherapy Products, H2 2015 21
  • Number of Products by Top 10 Targets, H2 2015 22
  • Number of Products by Stage and Top 10 Targets, H2 2015 22
  • Number of Products by Top 10 Mechanism of Actions, H2 2015 24
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24
  • Number of Products by Top 10 Routes of Administration, H2 2015 26
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
  • Number of Products by Top 10 Molecule Types, H2 2015 28
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015 28
Back to Top